Oncosil announces third patient has surgical resection

Company News

by Anna Napoli

Medical device company, Oncosil (ASX:OSL) has announced a third patient in its global study has undergone a surgical resection.

The business is conducting a global pancreatic cancer clinical study.

The first patients in the trial have been successfully implanted with Oncosil device.

The company says the device continues to be well tolerated with no safety concerns to date.

Shares in Oncosil (ASX:OSL) are trading 4.17 per cent higher to 13 cents.

Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.